We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the long term, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.
Introduction
Polo-like kinases (Plks) are a family of evolutionarily conserved serine/threonine kinases, which have an Nterminal catalytic kinase domain and highly conserved C-terminal sequences termed the polo-box domain. Among them, mammalian Plk1 and its M-phase homologs in other organisms are the most extensively studied. They are involved in many cellular events critical for cell division, including centrosome maturation and separation, mitotic entry, bipolar spindle formation, sister chromatid segregation and cytokinesis (Barr et al., 2004) . Plk1 expression is closely linked to cell proliferation. Actively proliferating cells usually have a higher Plk1 level than differentiated cells (Winkles and Alberts, 2005) .
Polo-like kinase 1 is proposed to play a role in tumorigenesis and oncogenic transformation (Eckerdt et al., 2005; Takai et al., 2005) . Plk1 overexpression is positively correlated with aggressiveness in a variety of human tumors, including melanomas, gliomas, nonsmall-cell lung, head and neck, esophageal, gastric, breast, ovarian, endometrial, colorectal and thyroid cancers (Wolf et al., 1997; Knecht et al., 1999 Knecht et al., , 2000 Strebhardt et al., 2000; Eckerdt et al., 2005; Takai et al., 2005) . Patients with a moderate Plk1 expression level usually survive longer than those with a high Plk1 level. Thus, Plk1 has been proposed as a new prognostic marker for many types of malignancies (Eckerdt et al., 2005; Takai et al., 2005) . Moreover, inhibition of Plk1 with various techniques, such as RNA interference (RNAi) and small-molecule inhibitor, results in growth arrest or apoptosis in cancer cells and inhibits xenograft tumor growth in nude mice (Liu and Erikson, 2003; Spankuch et al., 2004; Gumireddy et al., 2005) . Therefore, Plk1 is an intriguing target for therapeutic intervention against cancer (Strebhardt and Ullrich, 2006) .
We previously reported that Plk1 depletion led to apoptosis in cancer cells, that cancer cells with a p53-deficient background were more sensitive to Plk1 depletion-induced cell death than those with wild-type p53 and that DNA damage and cell death could occur independently of p53. By targeting different sites of Plk1, a series of Plk1 hypomorphs was generated. The different kinetics of cell-cycle progression of these hypomorphs suggests that different levels of Plk1 activity may be required for different phases of mitosis, with the level required for mitotic entry lower than that necessary for mitotic progression. The lentivirus-based RNAi approach allowed us to expand our study to normal cell lines. In striking contrast to cancer cells, normal hTERT-RPE1 and MCF10A cells were much less sensitive to Plk1 depletion; no apparent cell proliferation defect or cell-cycle arrest was observed after Plk1 depletion (Liu et al., 2006) . However, the population of lentivirus-infected cells may be heterogeneous due to different integration sites of the proviruses or different copy numbers of the proviruses inserted into the genome. To obtain a homogenous population of cells, we cloned individual lentivirusinfected cells for this study.
Results
Proliferation of hTERT-RPE1 Plk1-depleted clones HTERT-RPE1 is a human retinal pigment epithelial (RPE) cell line that stably expresses human telomerase reverse transcriptase (hTERT). Although immortalized by sustained telomerase activity, hTERT-RPE1 cells maintain a normal phenotype and are nontransformed (Bodnar et al., 1998; Jiang et al., 1999) . Lentivirus targeting Plk1-coding region 1424-1444 was used to infect hTERT-RPE1 cells, and four Plk1-depleted clones, 2, 4, 5 and 6, were selected.
Polo-like kinase 1 was efficiently depleted, with residual Plk1 levels higher in clones 2 and 5 than in clones 4 and 6 (Figure 1a ). Their proliferation rates were reduced (Figure 1b) , and their doubling time was increased 40-100% (Figure 1c ). These clones showed altered morphology; their microtubule network was elongated compared with control ( Figure 1d ).
HTERT-RPE1 Plk1-depleted clones were delayed at S phase Although they grew slowly, hTERT-RPE1 Plk1-depleted clones showed no signs of cell death. We then attempted to determine where cell-cycle progression was delayed. As shown in Figure 2a , an asynchronous population of clone 6 had a G1 shoulder, indicating that a higher percentage of clone 6 cells were in early S phase. A 5-bromodeoxyuridine (BrdU)-labeling experiment was performed to measure DNA synthesis in these cells (Figures 2b and c) . In a 2-h labeling period, 23% of clone 4 and 46% of clone 6 cells incorporated BrdU, whereas 13% of the control population incorporated BrdU. These results showed that in an asynchronous population, a higher percentage of Plk1-depleted cloned cells were undergoing DNA synthesis. We then synchronized these cells by serum starvation and monitored cell-cycle progression after serum stimulation (Figure 2d ). At 16 h after stimulation, both control and clone 4 entered S phase, as shown by the appearance of the G1 shoulder. By 24 h, control had nearly finished S phase, whereas clone 4 had not. Taken together, these data suggest that the slower growth rates of Plk1-depleted clones were due to their slow progression through S phase. As Plk1-depleted clones progressed slowly through S phase, the S-phase checkpoint may have been activated. Indeed, we found that p53 was upregulated and one of p53's downstream targets, the CDK inhibitor p21, was also upregulated (Figure 2e ). p38, a mitogen-activated protein (MAP) kinase usually phosphorylated and activated in G1 arrest in response to various cellular stresses, was not activated, indicating an S-phase arrest rather than G1 arrest (data not shown). The activation of this intra-S-phase checkpoint led us to speculate that in Plk1-depleted cells, cell-cycle progression was delayed due to DNA damage. Phosphorylation of Chk2 confirmed activation of the DNA-damage checkpoint ( Figure 2e ). To directly assess DNA damage, we performed a comet assay, which detects minor levels of DNA damage ( Figure 2f ; Angelis et al., 1999) . All clones displayed comet tails indicative of DNA damage, whereas the control did not. The DNA damage is probably not extensive, as these cells could apparently continue the cell cycle once the damage has been repaired.
MCF10A Plk1-depleted clones with mild depletion showed no obvious phenotype MCF10A is an immortalized, nontransformed mammary epithelial cell line (Soule et al., 1990) . Four MCF10A Plk1-depleted clones, 3, 5, 9 and 12, were generated. Clones 3, 5 and 9, with minimal Plk1 depletion, showed no obvious phenotype (Figure 3a ; Supplementary Figure 1) . However, one clone, clone 12, was very severely depleted of Plk1 and showed a different phenotype.
MCF10A Plk1-depleted clone 12 was blocked at G2/M and underwent apoptosis MCF10A clone 12 had very severe Plk1 depletion. Its Plk1 level was much lower than that in control and other clones (Figure 3a) . Clone 12 proliferated more slowly than the control, but the difference was minor, with the doubling time 20% longer (Figures 3b and c) . Almost 100% of clone 12 cells were positively stained with Ki-67, indicating that most cells were actively proliferating (Figure 3d ; Gerdes et al., 1984) . However, the cell-cycle distribution of clone 12 was different from that of the control. As shown in Figure 3e , clone 12 had a greater 4N DNA peak and a subgenomic DNA peak, indicating that a greater percentage of clone 12 cells were in G2/M and some were undergoing apoptosis. Staining with phospho-histone H3 antibody, a mitosis marker, showed that clone 12 had a mitotic index twice that of control (Figure 3f ). To follow their cell-cycle progression, clone 12 cells were synchronized at the G1/S boundary by double thymidine block. Cells were either harvested for fluorescent-activated cell sorting (FACS) analysis or fixed for phospho-histone H3 immunofluorescent staining at different times after release (Figures 3h-k; Supplementary Tables 1 and 2 ). As shown in Figure 3h , both control and clone 12 entered S phase by 2 h and finished S phase by 6 h. However, control completed M phase after 12 h, whereas a significant fraction of clone 12 displayed a 4N DNA content at that time. Phospho-histone H3 staining showed that the control entered M phase by 8 h, reached mitotic peak at 9 h and completed mitosis around 12 h (Figure 3i ). Clone 12 entered M phase by 9 h, a 1-h delay compared with the control. In addition, the mitotic peak of clone 12 was lower than that of the control, and there was no sign of mitotic exit by 12 h. Cell synchronization by serum starvation showed similar results (Supplementary Figure 2) . Taken together, these data suggest that clone 12 progressed slowly through G2/M, and a fraction of the cell population was blocked there.
At all times after release, a fraction of clone 12 cells were undergoing apoptosis as shown by the subgenomic DNA peak (Figure 3h ). Caspase 3 was cleaved in some clone 12 cells, and the nuclei of these cells were either fragmented or disappearing, confirming activation of the apoptotic program (Figure 3g) . At 12 h, 13% of clone 12 cells were multinucleated, and some had a multipolar spindle (Figures 3j and k) . These mitotic defects and cell death suggest that some clone 12 cells were undergoing mitotic catastrophe.
To determine whether the DNA-damage checkpoint was activated before apoptosis, gH2AX immunofluorescent staining, anti-p53 and anti-Chk2 western blotting were performed (Figures 4a-c) . Clone 12 cells showed various intensity of positive gH2AX staining. p53 was upregulated, and Chk2 was phosphorylated, as shown by the slower-migrating form, indicative of checkpoint activation. To determine whether checkpoint activation played a protective role in clone 12, cells were treated with different concentrations of caffeine, an ATM/ATR inhibitor, for 2 days and harvested for further analysis (Figures 4d and e) . Checkpoint inhibition by caffeine potentiated cell death in a concentration-dependent manner (Figure 4e ). It also attenuated the upregulation of p53 (Figure 4d ). These data suggest that the DNAdamage checkpoint was activated in clone 12 and it first functioned to arrest the cell cycle and protect cells from mitotic catastrophe.
We also examined the status of the DNA-damage checkpoint in a heterogeneous population of HeLa and MCF10A cells at different times after Plk1 depletion (Supplementary Figure 3) . Chk2 was only modestly phosphorylated in HeLa after Plk1 depletion, but showed robust phosphorylation in MCF10A.
Plk1 depletion activates checkpoint M Lei and RL Erikson
The degree of Chk2 activation in MCF10A attenuated with time and was inversely related to the extent of Plk1 depletion. This reflects the presence of an intact checkpoint in normal cells, but not in cancer cells. This difference might partially explain the more severe and rapid cell death in cancer cells after Plk1 depletion, as there is no functional checkpoint to protect the cells before mitotic catastrophe takes place (Castedo et al., 2004) . The fact that checkpoint inhibition in MCF10A Plk1-depleted clone 12 potentiated cell death also supports this notion. 
Control

Discussion
The data presented here show that Plk1 depletion reduced the growth rate of hTERT-RPE1 cells, apparently due to delayed progression through S phase and/or delay due to repair of DNA damage. Plk1 interacts with the minichromosome maintenance (Mcm) proteins (Tsvetkov and Stern, 2005) ; budding yeast Plk Cdc5 interacts with the Dbf4 subunit of Dbf4/Cdc7 kinase, which activates the pre-replication complex (Hardy and Pautz, 1996) , suggesting possible functions of Plk1 in S phase. Alternatively, but not exclusively, Plk1 depletion may cause a low level of DNA damage, which activates the S-phase checkpoint. Checkpoint activation arrests the cell cycle and allows DNA repair. It is very likely that it is the insufficiency of Plk1 function in S phase that causes DNA damage. Interestingly, endogenous Plk1 co-immunoprecipitates with basal forms as well as with slower migrating forms of Mcm7, induced in response to DNA damage, suggesting possible roles of Plk1 in DNA synthesis both in the unperturbed cell cycle and in response to genotoxic stress (Tsvetkov and Stern, 2005) .
An interesting phenomenon is the morphological change of hTERT-RPE1 clones. Under cell culture conditions normally used for hTERT-RPE1, they have lost many differentiated features. They show fusiform morphology and have lost pigmented granules 
Plk1 depletion activates checkpoint
M Lei and RL Erikson (Rak et al., 2006) . Plk1 depletion slows their proliferation and may initiate differentiation. Activated MAP kinase kinase induces transdifferentiation of RPE into a neural-like epithelium (Galy et al., 2002) . In Plk1-depleted clones, MAP kinase kinases Mek1/2 and MAP kinases Erk1/2 are phosphorylated (data not shown). It is possible that the Plk1-depleted hTERT-RPE1 cells are transdifferentiating into neural retina. The phenotypes of hTERT-RPE1 clones were more dramatic than we previously reported. The heterogeneous population studied previously appears to display the characteristics of cells with growth advantages and underrepresent those with growth defects. Moreover, previous experiments were performed shortly after infection, whereas current studies were performed after multiple cell divisions necessary for cloning. If Plk1 depletion caused only some minor effects, they may accumulate with time to show an observable phenotype.
The effects of Plk1 depletion in hTERT-RPE1 cells reported here appear to differ from the results obtained with the ATP-competitive Plk1 inhibitor, BI 2536, which showed that after a 2-h treatment of 100 nM inhibitor, 70% of the mitotic cells displayed a typical 'Polo' phenotype (Steegmaier et al., 2007) . RNAi lowers overall protein level, but does not interfere with the function of residual Plk1. In contrast, BI 2536 inhibits Plk1's enzymatic activity, but its polo-box domain is still functional and is able to interact with its substrates and binding partners. The inhibitor-bound Plk1 might have a dominant-negative effect over the residual Plk1. BI 2536 also inhibits Plk2 and Plk3 activity at nanomolar concentrations (the working concentrations in that study were enough to inhibit these two kinases as well). Moreover, the authors used asynchronous cells and only mitotic cells were examined for analysis of the 'Polo' phenotype.
The MCF10A Plk1-depleted clones 3, 5 and 9 had modest levels of depletion and did not show any obvious phenotype (Supplementary Figure 1) , consistent with our previous findings that normal cells survive with lower Plk1 levels. In contrast, clone 12 had very low level of Plk1, and a fraction of the cells showed phenotypes similar to Plk1 depletion in cancer cells, such as G2/M arrest and apoptosis. Taken together, these data suggest that Plk1 is essential for normal cell proliferation. However, it should be noted that the degree of Plk1 depletion in MCF10A clone 12 or some hTERT-RPE1 clones would result in death of an entire HeLa cell population in 3-4 days.
In the case of cancer cells, although they have accumulated mutations that facilitate rapid growth, they have also accumulated many changes in cellular machinery, which may hamper their proliferation. In this sense, they may require a greater contribution from Plk1 depletion activates checkpoint M Lei and RL Erikson certain factors for rapid progress through the cell cycle. Plk1 is clearly an excellent candidate to fulfill this role. This might partially explain why cancer cells need much higher levels of Plk1 for proliferation. In this regard, Plk1 may be an enzyme to which cancer cells have become 'addicted' in a manner proposed by Weinstein and Joe (2006) . Our data suggest that Plk1 depletion can lead to checkpoint activation not only in G2/M, as in MCF10A clone 12, but also in S phase, as in the hTERT-RPE1 clones. Under both conditions, DNA damage is likely the cause of checkpoint activation. DNA topoisomerase IIa (topoIIa) was recently identified as an in vitro substrate of Plk1 (X Liu, personal communication). It is possible that Plk1 depletion causes DNA damage because of its regulatory function over topoIIa. Dysfunction of topoIIa might generate DNA strand breaks and activate the DNA-damage checkpoint. In contrast, Plk1 is a target of the DNA-damage checkpoint and is required for checkpoint recovery after the damage has been completely repaired (Smits et al., 2000; Mamely et al., 2006) . Plk1 interacts with several checkpoint components, such as p53 and Chk2 (Tsvetkov et al., 2003; Ando et al., 2004) . The functional relationship between Plk1 and the checkpoint requires additional studies.
Considering the different nature of different cell lines, it is not surprising that hTERT-RPE1 and MCF10A Plk1-depleted clones have different phenotypes. Their tissue origin is different and they are immortalized in different ways. Due to these differences, Plk1 depletion might cause a subset of defects in one cell line, but another subset in the other cells. Our observation that normal cells require a minimal level of Plk1 for proliferation does not argue against the possibility of Plk1 being a good target for cancer therapy, because the two most promising therapeutic approaches, small chemical inhibitors and delivery of RNAi vectors, cannot completely block Plk1 activity, and residual activity is likely to be sufficient for the surrounding normal cells but not the targeted cancer cells.
Materials and methods
Lentivirus production Lentiviruses were produced as described previously (Liu et al., 2006) .
Generation of Plk1-depleted clones
Cells were infected with lentivirus targeting Plk1 sequence AGATCACCCTCCTTAAATATT. After 2 days' selection of infection-positive cells with 2 mg ml À1 puromycin, floating cells were washed away with phosphate-buffered saline and attached cells were reseeded very sparsely to allow colony formation. Colonies were harvested and cultured for further experiments.
Cell culture and synchronization Cells were cultured as described previously (Liu et al., 2006) . To synchronize MCF10A cells, cells were treated with 2.5 mM thymidine for 17 h, released for 7 h and treated with thymidine again for 17 h. HTERT-RPE1 cells were synchronized by serum starvation for 3 days. Cells were then stimulated with 20% fetal bovine serum.
Cell-cycle analysis
For FACS analysis, cells were collected by trypsinization, washed with phosphate-buffered saline and fixed in cold 70% ethanol. After fixation, cells were incubated with 200 mg ml
À1
RNaseA and stained with 50 mg ml À1 propidium iodide for 30 min at room temperature. Flow cytometry was carried out with a FACScan instrument (Becton Dickinson, Franklin Lakes, NJ, USA).
5-Bromo-2 0 -deoxy-uridine labeling and detection kit I (cat. no. 1 296 736) was purchased from Roche Applied Science (Indianapolis, IN, USA).
Immunoblotting and immunofluorescent staining
Western blotting was performed as described previously; cells were fixed and stained as described previously (Liu et al., 2006) . Plk1 and phospho-histone H3 antibodies were purchased from Upstate (Billerica, MA, USA); p-Chk2, p-Erk1/2, p-Mek1/2, cleaved caspase 3 and gH2AX antibodies were from Cell Signaling (Danvers, MA, USA); p53 antibody was from Oncogene (San Diego, CA, USA); p21, Erk2 and Chk2 antibodies were from Santa Cruz (Santa Cruz, CA, USA); a-tubulin antibody was from Sigma (St Louis, MO, USA) and Ki-67 antibody was from BD Biosciences (Franklin Lakes, NJ, USA).
Comet assay
CometAssay reagent kit (cat. no. 4250-050-K) was purchased from Trevigen (Gaithersburg, MD, USA).
